MAPT and neurodegenerative disease: Over the past years, active and passive antibody approaches targeting different extracellular (Aβ) and intracellular (Tau, α-synuclein, poly-GA) aggregating proteins have emerged as promising options for the treatment of neurodegenerative diseases [34].